CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cadrenal Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.06−0.03 (-2.75%)
Close on Oct 19, 2026
- Market cap
- $3.09M
- P/E (TTM)
- –
- Dividend yield
- 1556.60%
Share price
−$12.57 (−92.22%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.09M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.75
- Dividend yield
- 1556.60%
- Free cash flow yield
- -408.25%
Fundamentals
- Net income
- -$11.54M
- EPS, diluted
- -$4.92
- Free cash flow
- -$12.61M
- Book value per share
- $1.40
- Diluted shares
- 3M
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
-$11.65M
Net income
-$11.54M
EPS, diluted
-$4.92
Free cash flow
–
Reported periodTrailing twelve months